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Abstract
Background and Aims: Transjugular intrahepatic portosys-
temic shunt (TIPS) is used for decompressing clinically sig-
nificant portal hypertension. The aims of this study were to 
evaluate clinical outcomes and adverse events associated 
with this procedure. Methods: Retrospective single-center 
study including 78 patients submitted to TIPS placement be-
tween January 2015 and November 2018. Follow-up data 
were missing in 27 patients, and finally 51 patients were in-
cluded in the study sample. Data collected from individual 
registries included demographics, comorbidities, laboratory 
results, complications, and clinical results according to the 
indication. Results: Average pre-TIPS portosystemic pres-
sure gradient decreased from 18.1 ± 5 to 6 ± 3 mm Hg after 
TIPS placement. Indications for TIPS were refractory ascites 
(63%, n = 49), recurrent or uncontrolled variceal bleeding 
(36%, n = 28), and Budd-Chiari syndrome (1.3%, n = 1). TIPS-
related adverse events occurred in 29/51 (56.8%) patients, 
with hepatic encephalopathy (HE) in 21 (41%) patients, sep-
sis in 3, liver failure in 2, hemolytic anemia in 1, acute pulmo-
nary edema in 1, and capsular perforation in 1 patient. Mean 
follow-up was 15.7 ± 15 months. First-month mortality was 
11.7% (n = 6) (sepsis, n = 3; acute liver failure, n = 2; and re-
currence of variceal bleeding, n = 1) and was significantly 
higher for patients with Child-Pugh > 9 points (p = 0.01), 
model of end-stage liver disease (MELD) scores > 19 (p = 
0.02), and for patients with a history of HE before the proce-
dure (p = 0.001). Older age (p = 0.006) and higher levels of 
creatinine (p = 0.008) were significantly higher in patients 
developing HE after TIPS. Ascites persisted in 21.2% (7/33 
patients) and was more frequent in patients with lower base-
line albumin levels (p = 0.003). Recurrent variceal bleeding 
occurred in 22% (n = 4/18 patients) and was more frequent 
in patients with lower baseline hemoglobin levels (p = 0.03). 
Conclusion: TIPS is effective in up to 80% of patients pre-
senting with variceal bleeding or refractory ascites. Careful 
patient selection based on age and HE history may reduce 
adverse events after TIPS.
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Estudo retrospetivo de colocação de shunt 
portossistémico transjugular intrahepático na 
hipertensão portal cirrótica
Palavras Chave
Shunt portossistémico transjugular intra-hepático · 
Hipertensão portal
Resume
Introdução e Objectivos: O shunt portossistémico tran-
sjugular intra-hepático (TIPS) é usado para descompressão 
de hipertensão portal hepática clinicamente significativa. 
Os objetivos deste estudo foram avaliar os resultados clíni-
cos e efeitos adversos associados a este procedimento.  
Métodos: Estudo retrospectivo de centro único, incluindo 
78 pacientes submetidos ao procedimento entre Janeiro de 
2015 e Novembro de 2018. Os dados de seguimento es-
tavam ausentes em 27 doentes, tendo sido incluídos 51 
doentes na análise. Os dados colhidos de registos individ-
uais incluíram dados demográficos, comorbilidades, resul-
tados laboratoriais, complicações e resultados clínicos, de 
acordo com a indicação. Resultados: O gradiente médio de 
pressão portossistémica pré-TIPS foi de 18.1 ± 5 mm Hg, 
que diminuiu para 6 ± 3 mm Hg. Indicações para TIPS foram 
ascite refratária (65%, n = 33) e hemorragia varicosa recor-
rente/refratária (35%, n = 18). As complicações relacionadas 
ao TIPS ocorreram em 29 doentes (56.8%): encefalopatia 
hepática (EH) em 21 doentes, sépsis (n = 3), insuficiência 
hepática (n = 2), anemia hemolítica (n = 1), edema pulmo-
nar agudo (n = 1) e perfuração capsular (n = 1). O seguimen-
to médio foi de 15.7 ± 15 meses. A mortalidade no primeiro 
mês foi de 11.7% (n = 6) (sépsis, n = 3; insuficiência hepática 
aguda, n = 2; recorrência de hemorragia varicosa, n = 1), e 
foi significativamente mais frequente em doentes com 
Child-Pugh > 9 pontos (p = 0.01), pontuação de MELD > 19 
pontos (p = 0.02) e história de EH prévia ao procedimento 
(p = 0.001). Doentes que desenvolveram EH tinha mais fre-
quentemente idade avançada (p = 0.006) e níveis mais el-
evados de creatinina (p = 0.008). A ascite persistiu em 21.2% 
(7/33 doentes), mais habitualmente em doentes com níveis 
mais baixos de albumina basal (p = 0.003). Hemorragia var-
icosa recorrente ocorreu em 22% (n = 4/18 doentes), em 
associação com níveis mais baixos de hemoglobina (p = 
0.03). Conclusão: O TIPS é eficaz em 80% dos doentes que 
apresentam hemorragia varicosa ou ascite refratária. Even-
tos adversos podem ser reduzidos através da seleção de 
doentes, com base na idade e história de EH.
© 2020 Sociedade Portuguesa de Gastrenterologia  
Publicado por S. Karger AG, Basel
Introduction
The potential utility of transjugular intrahepatic por-
tosystemic shunt (TIPS) placement was first proposed in 
1969 by J. Rosch. The first TIPS procedure, performed in 
1988 by M. Rössle, was done with the purpose of relieving 
portal hypertension [1]. Several studies and international 
guidelines have addressed the potential usefulness of this 
procedure in the management of cirrhosis complications 
refractory to conventional therapy. One of the most no-
table advances in this technique has been the use of ex-
pandable PTFE (polytetrafluorethylene)-covered stents, 
which significantly lowered occlusion rates compared to 
the previously used bare-metal stents, thereby improving 
long-term stent patency. These stents are now considered 
standard of care [1–4]. 
Refractory ascites and recurrent or treatment-refrac-
tory acute variceal bleeding are the two main established 
indications for TIPS placement. The value of an early 
TIPS placement in patients with acute variceal bleeding 
with high risk of early rebleeding has also been proposed 
in patients with Child-Pugh score ≤13 [1, 5].
The major complication of this procedure continues 
to be hepatic encephalopathy (HE), requiring appropri-
ate selection of patients and preferential use of shunts 
with smaller diameters. Selection criteria and liver func-
tion assessment can be performed using several scoring 
systems. The model of end-stage liver disease (MELD) 
score was developed to predict early mortality after TIPS 
and is now used as a severity index of liver function. In 
addition, high Child-Pugh scores are regarded as a rela-
tive contraindication to TIPS placement [1, 4]. 
Liver transplantation remains the definitive treatment 
for complications related to cirrhosis, but the lack of ad-
equate organ supply can lead to higher mortality and 
dropout while on the liver transplant waiting list. In this 
context, TIPS placement assumes a primary role as a 
bridge to liver transplantation.
We sought to study the clinical outcomes and adverse 
events related to TIPS placement in a cohort of patients 
with decompensated cirrhosis.
Subjects and Methods
Design, Setting, and Participants
This is a single-center retrospective study that included all con-
secutive adult patients (≥18 years) diagnosed with liver cirrhosis 
who underwent TIPS placement for treatment of portal hyperten-
sion related complications at the Interventional Radiology Unit of 
the Curry Cabral Hospital (Lisbon, Portugal) between January 
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2015 and November 2018. We started patient enrolment at this 
time point due to the quality of data recorded from then on. We 
included patients with a diagnosis of liver cirrhosis and complica-
tions related to portal hypertension submitted to the procedure 
due to acute refractory or recurrent variceal bleeding that could 
not be controlled with conventional therapy or refractory ascites. 
Patients undergoing liver transplantation were censored during 
follow-up at the date of liver transplant. Given the observational 
character of the study, the local ethics committee waived the need 
for individual informed consent. The principles of the Declaration 
of Helsinki were respected throughout the study [6]. 
Procedure, Data Collection, and Endpoints
All procedures were performed in the Interventional Radiology 
Unit by 3 interventional radiologists with 20, 9, and 4 years of ex-
perience; TIPS was performed using a 10-mm expandable PTFE-
covered stent (Viatorr® TIPS endoprosthesis; Gore, Flagstaff, AZ, 
USA). All TIPS procedures were performed under general anes-
thesia with a portosystemic pressure gradient (PPG) measured be-
fore and after successful completion of the procedure. TIPS pa-
tency was evaluated by Doppler ultrasound 2–8 weeks after the 
procedure. Data on the study population characteristics were re-
trieved from individual patient clinical files. The measured out-
comes were: technical/hemodynamic success, procedure-related 
adverse events, first-month mortality following the procedure and 
orthotopic liver transplant (OLT)-free survival. Technical success 
was considered as effective creation of a shunt between the hepat-
ic and portal venous system, and hemodynamic success as a de-
crease in PPG to ≤12 mm Hg or a reduction of at least 20%.
Clinical success concerning recurrent bleeding and ascites re-
sponse according to TIPS indication was evaluated. Partial ascites 
response was considered when no further paracentesis was neces-
sary despite the presence of clinically detectable ascites. Total re-
sponse was defined as absence of ascites with or without the use of 
diuretics.
Data Analysis
Baseline characteristics are described as numbers (%) for cat-
egorical variables and medians with interquartile ranges (IQR) or 
means with standard deviations (SD) for continuous variables. 
Baseline characteristics were compared between patients with dif-
ferent outcomes by χ2 test for qualitative variables and Student’s t 
test or Mann-Whitney test for quantitative variables. Statistical 
significance was set at p < 0.05. Statistical analysis was performed 
using SPSS v25 (2017).
Results
Study Population and Technical Outcomes
In this study period, 78 procedures were performed 
with 97.4% (n = 76) technical success. Hemodynamic suc-
cess, defined by a final PPG of 12 mm Hg or less, or a re-
duction of at least 20%, was achieved in all patients with 
technical success (n = 76). In the 1 patient with final PPG 
> 12 mm Hg, reduction was superior to 20%. Indications 
for TIPS were refractory ascites (63%, n = 49), recurrent 
or uncontrolled variceal bleeding (36%, n = 28), and 
Budd-Chiari syndrome (1.3%, n = 1). Pre-TIPS mean 
PPG was 18.1 ± 5 mm Hg, which decreased to 6 ± 3 mm 
Hg after TIPS. The mean decrease was 12 ± 5 mm Hg.
Two patients with technical failure of TIPS placement 
were excluded. In addition, 16 patients whose indication 
was refractory ascites and 9 patients whose indication was 
variceal bleeding were excluded due to loss of follow-up. 
Therefore, the final study sample included 51 patients 
with indications for TIPS being refractory ascites (65%, 
n = 33) and uncontrolled or early severe recurrent vari-
ceal bleeding (35%, n = 18).
The mean follow-up time until liver transplant, death, 
or date of data collection was 15.7 ± 15 months. Fifteen pa-
tients (19.7) underwent liver transplantation for end-stage 
liver disease 8 ± 6 months after TIPS placement. Most pa-
Table 1. Baseline main demographic and clinical characteristics of 
the study population (n = 51)
Sex, male 38 (75%)
Age, years 56±12
Indication for TIPS, ascites/variceal 
bleeding 33/18 (65/35%)
Child-Pugh
A
B
C
3 (5.8%)
41 (80.4%)
7 (13.7%)
MELD 13.7±5.2
MELD-Na 15.8±6
Etiology of liver disease
Alcohol
Both alcohol + HCV/HBV
Cryptogenic
HCV
PBC
NASH
Wilson disease
29 (57%)
9 (18%)
5 (10%)
3 (6%) 
2 (4%)
2 (4%)
1 (2%)
Previous hepatic encephalopathy 7 (14%)
Comorbidities (hypertension, coronary 
artery disease, and type 2 diabetes) 16 (31%)
Serum Na, mEq/L 139±5.3
INR 1.3±0.19
Creatinine, mg/dL 1.4±0.82
Total bilirubin, mg/dL 1.95±2.9
Albumin, mg/dL 32.6±5.8
Platelet count, ×109/L 128±71.3
Hemoglobin, g/dL 10.2±2.6
Continuous variables are presented as means ± SD, categorical 
variables as numbers (%). HBV/HCV, hepatitis B/C virus; INR, 
international normalized ratio; MELD, model of end-stage liver 
disease; NASH, nonalcoholic steatohepatitis; PBC, primary biliary 
cirrhosis; TIPS, transjugular intrahepatic portosystemic shunt.
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tients were male (75%, n = 38), with a mean age of 56 ± 12 
years (22–76). Cirrhosis was most frequently due to alcohol 
(57%, n = 29), and both alcohol and hepatitis C/B (18%, 
n = 9). Other etiologies along with baseline data are sum-
marized in Table 1. The Child-Pugh score was class A in 3 
patients, B in 41 patients, and C in 7 patients. Mean MELD 
score was 13.7 ± 5.2 (7–33) and MELD-Na 15.8 ± 6 (7–36). 
Forty-seven patients (92%) had previous episodes of cir-
rhosis decompensation and a prior episode of HE in 14% 
(n = 7). Status of alcohol consumption was not registered 
in all patients, for whom these data were not included.
Adverse Events
Adverse events related to TIPS occurred in 29 patients 
(56.8%), most of them due to development or worsening 
of HE (21 patients; 41%); in the remainder, adverse events 
were attributable to sepsis (n = 3), hepatic failure (n = 2), 
hemolytic anemia (n = 1), acute pulmonary edema (n = 
1), and capsular perforation (n = 1). HE occurred in 21 
patients (41%) during follow-up, with 19 patients (90%) 
developing grade I–II HE according to the West-Haven 
classification and 2 patients with grade III HE. The me-
dian time until HE development was 1 (2.8) month after 
the procedure. Older age and higher levels of creatinine 
were significantly higher in patients developing HE 
(Table 2). Concerning shunt dysfunction, stent thrombo-
sis occurred in 2 patients: recanalization with anticoagu-
lation was possible in 1 patients, and, in another patient, 
stenosis was successfully treated with angioplasty.
In this population, 6 patients (11.7%) died within 1 
month after TIPS procedure. Early mortality was due to 
sepsis (n = 3), acute hepatic failure (n = 2), and recurrence 
of variceal bleeding (n = 1). 
Patients who died in the first month after TIPS place-
ment had a significantly higher baseline Child-Pugh score 
(33% with score C vs. 6% with score A or B; p = 0.006) and 
MELD score, and a significantly higher rate of prior his-
tory of encephalopathy (Table 3). The indication for TIPS 
placement (ascites vs. variceal bleeding) was not different 
between patients who died versus those who survived. 
OLT-free survival at 1 month and 1 year was 88.3 and 
60%, respectively. From the 15 patients who underwent 
liver transplantation, 3 (20%) died after a median time of 
0.8 (4.8) months. Patients who died after OLT had sig-
nificantly higher baseline Child-Pugh and MELD scores 
(online suppl. Table 1; for all online suppl. material, see 
www.karger.com/doi/10.1159/000507894).
Recurrent/Uncontrolled Bleeding
Among the 18 patients in whom the indication for 
TIPS placement was refractory/recurrent variceal bleed-
ing, a new episode of variceal bleeding was reported in 4 
patients (22%), in 3 of them within the first 30 days after 
the procedure. These patients had post-TIPS PPG medi-
an value of 8 mm Hg, but none > 12 mm Hg. Patients who 
experienced rebleeding had significantly lower baseline 
hemoglobin values (online suppl. Table 2). In 1 patient, 
outcome was fatal. Concerning the other 3 patients, 2 of 
them were submitted to elastic banding and 1 to Seng-
staken-Blakemore tube placement. PPG was remeasured 
in 2 patients, both with > 12 mm Hg, submitted to TIPS 
dilation. 
Table 2. Comparison of baseline data of patients with versus 
without hepatic encephalopathy (HE) development or worsening
Variables HE 
(n = 21)
No HE 
(n = 30)
p 
value
Age, years 59 (10) 51 (13) 0.006
Child-Pugh 8 (2) 7.5 (2) 0.3
MELD 12 (6) 13 (6.5) 0.5
Baseline creatinine, mg/dL 1.58 (0.9) 0.96 (0.8) 0.008
Baseline albumin, mg/dL 33.5 (10.5) 31 (9) 0.2
Baseline serum Na+, mEq/L 134 (8) 137 (12) 0.08
Baseline platelet count, ×109/L 127 (82) 97 (127) 0.49
PPG reduction, mm Hg 12 (5) 12 (9) 0.55
Final PPG, mm Hg 6 (2.5) 6 (5.5) 0.4
Continuous variables are presented as medians (IQR). PPG, 
portosystemic pressure gradient. See legend to Table 1 for further 
information.
Table 3. A comparison of baseline data between patients who died 
and those who survived after TIPS
Variables Death 
(n = 6)
Survival 
(n = 45)
p 
value
Age, years 57 (15.5) 59 (17.5) 0.1
Indication, n 
Ascites
Variceal bleeding
3 (9%)
3 (18%)
30 (91%)
14 (82%)
0.3
Child-Pugh 10.5 (3.3) 8 (2) 0.01
MELD 18.8 (13.5) 12 (7) 0.02
Previous encephalopathy, n 4 (57%) 3 (5%) 0.001
PPG reduction, mm Hg 13.5 (5.2) 11 (2) 0.7
Final PPG, mm Hg 5.5 (2) 6 (4.3) 0.5
Continuous variables are presented as medians (IQR), 
categorical variables as numbers (%). PPG, portosystemic pressure 
gradient. See legend to Table 1 for further information.
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Ascites Response
Among the 33 patients with refractory ascites and docu-
mented follow-up, a partial or complete response was con-
firmed in 11 (33.3%) and 15 (45.5%), respectively, and no 
response in 7 patients (21.2%). These last patients had a 
median value of 7 mm Hg after TIPS PPG; 1 patient had 14 
mm Hg, with pre-TIPS PPG of 31 mm Hg. Significantly 
lower levels of baseline albumin were found in patients with 
failure of ascites control post-TIPS (online suppl. Table 3).
Discussion
Portal hypertension is an inevitable consequence of 
cirrhosis characterized by increased pressure gradient be-
tween the portal vein and the suprahepatic veins (hepatic 
venous pressure gradient > 5 mm Hg) [7]. Clinically sig-
nificant portal hypertension, defined as hepatic venous 
pressure gradient ≥10 mm Hg, is responsible for many 
important complications of cirrhosis, with 2 of the most 
common being variceal bleeding and ascites [8]. The de-
velopment of these complications marks the transition 
from a compensated to decompensated stage of cirrhosis, 
which is associated with a significant reduction in sur-
vival [9]. The TIPS procedure is used to decompress the 
portal venous system through its connection into the sys-
temic circulation, therefore preventing rebleeding from 
varices and/or reducing ascites formation; it can also be 
used for other complications, such as hepatic hydrotho-
rax or hepatorenal syndrome [10]. 
In patients with acute variceal bleeding, endoscopic 
treatment is initially preferred. However, it fails to control 
bleeding in 10–15% of cases [11]. In patients successfully 
treated with endoscopic band ligation, the risk of rebleed-
ing can be reduced by the use of nonselective β-blockers 
to 45%, by sequential endoscopic band ligation to 30%, 
and by a combination of both to around 25% [12]. Previ-
ous studies have demonstrated that in high-risk patients 
with Child-Pugh class C < 14 points or class B disease with 
active bleeding at presentation, the use of early TIPS 
(within 72 h after admission) was associated with im-
proved bleeding control and mortality [13, 14]. TIPS 
placement has also proven more effective in the preven-
tion of rebleeding than any of the previous pharmaco-
logical or endoscopic therapies [12].
Refractory ascites, defined as fluid which cannot be 
mobilized despite sodium restriction and high-dose di-
uretics, or reaccumulates after therapeutic paracentesis, 
occurs in about 5–10% of patients with cirrhosis [15]. In 
these patients, TIPS placement has shown better control 
of ascites than medical treatment [15]. Indications for 
TIPS in our cirrhotic population were refractory ascites, 
variceal bleeding not controlled by endoscopic band liga-
tion, or rebleeding of gastroesophageal varices, as in most 
cases [16]. In our study, technical success was 97.4%, 
which is in agreement with other reports [17]. Hemody-
namic success was achieved in all patients with technical 
success, as described elsewhere [18]. In patients with var-
iceal bleeding, it is well established that if the PPG after 
TIPS creation can be reduced to 12 mm Hg or less, the 
risk of bleeding will fall significantly [19]. Parvinian et al. 
[18] suggest a similar PPG threshold to control refractory 
ascites. In our population, even though 1 patient had a 
post-TIPS PPG > 12 mm Hg, TIPS was effective in reduc-
ing PPG values > 20% from baseline in all patients. 
First-month mortality is related to the clinical charac-
teristics of patients, ranging from 3 to 44% [20]. In our 
study, 30-day mortality was 11.7%, which is similar to that 
reported by Pan et al. [21]. Patients who died after TIPS 
placement had a significantly higher rate of previous HE 
and higher baseline Child-Pugh and MELD scores. Sur-
vival is associated with liver functional reserve [22]. MELD 
score was initially created to predict the 3-month mortal-
ity in patients undergoing elective TIPS placement [23]. 
As liver failure and portal hypertension deteriorate, serum 
bilirubin, INR, and creatinine levels rise, therefore in-
creasing MELD levels. Previous studies have indicated 
that MELD is useful in identifying patients at higher risk 
of early death [24, 25]. Regardless of TIPS indication, pa-
tients with higher Child-Pugh score tend to have poor sur-
vival [26]. Pre-TIPS HE has already been described as an 
independent risk factor for mortality after TIPS [20]. 
OLT-free survival ranges from 48 to 90% in patients un-
dergoing TIPS for variceal bleeding and from 48 to 91% 
when used for refractory ascites [5]. In our population, 
OLT-free survival at 1 month and 1 year was 88.3 and 60%, 
respectively. Patients who died after OLT presented sig-
nificantly higher baseline Child-Pugh and MELD scores, 
which are both associated with more advanced disease. 
The success rate of TIPS for controlling recurrent 
bleeding was satisfactory in our population, as only 22% 
experienced rebleeding. A recent meta-analysis analyzing 
24 studies from 12 different countries obtained similar 
results [27], confirming its superiority to endoscopic 
treatment for this purpose. A pre-TIPS lower hemoglobin 
value was significantly associated with rebleeding after 
TIPS, as also reported by Kim et al. [28]. Variceal embo-
lization performed as an adjunctive therapy during TIPS 
procedure has the potential to help preventing recurrent 
bleeding by occluding venous collateral channels [29]. 
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Development of ascites is a poor prognostic factor in 
patients with cirrhosis, with a 1- and 2–year mortality of 
about 40 and 50%, respectively, and a median survival of 6 
months once it becomes refractory to treatment [9]. In our 
population, TIPS placement was effective for refractory as-
cites, with response in 78.8% (n = 26) of patients (33.3% 
achieving partial and 45.5% complete response), as seen in 
other reports [22, 30]. In our study, patients in whom asci-
tes control failed were found to have significantly lower 
levels of baseline albumin, which is in line with the role of 
albumin in the pathophysiology of ascites [31].
The main complication of TIPS insertion is the devel-
opment or worsening of HE, ranging from 25 to 45% [32]. 
Metabolites present in the portal circulation requiring he-
patic detoxification bypass the liver through TIPS and en-
ter directly into the systemic circulation, contributing to 
post-TIPS HE [32]. Despite its relatively high rate, most 
patients with post-TIPS HE respond well to conservative 
treatment with dietary modification and medical therapy 
[33]. Only 3–7% of patients develop recurrent or refrac-
tory HE, which may need reduction or occlusion of the 
shunt as conservative treatment alone is not sufficient 
[17]. In our series, 41% (n = 21) of patients developed HE; 
older age and higher levels of creatinine were significant-
ly higher in those patients. Impaired renal function has 
been found to predict post-TIPS HE occurrence [34]. As 
liver disease deteriorates, it causes hemodynamic changes 
which decrease renal function. Patients will also be more 
susceptible to HE; possible explanations include a de-
crease in first-pass hepatic clearance of ammonia and an 
increase in splanchnic blood flow, which increases the 
amount of circulating ammonia [35]. A meta-analysis in-
cluding 30 studies with a total of 3,006 patients identified 
increased age as a robust predictor of post-TIPS HE [36]. 
The development of HE is also associated with shunt di-
ameter [37]. A possibility to reduce post-TIPS HE inci-
dence is the use of stents with a smaller diameter, there-
fore reducing the amount of blood shunted into the sys-
temic circulation [38]; however, it may be associated with 
less efficient control of portal hypertension [39]. The 
mean values of the final PPG compared between patients 
experiencing adverse events (namely HE), mortality, 
bleeding, or ascites control was not significantly different. 
These features highlight the fact that after a technically 
successful TIPS procedure, all outcomes depend on pa-
tient selection and probably timing of the procedure and 
not on the procedure itself. All technically successful 
TIPS procedures allowed for a hemodynamic success. 
The timing of the TIPS procedure also plays a crucial role 
(even though not evaluated in this study), as referral 
should not be delayed to the terminal stage of cirrhosis; 
late interventions are associated with higher morbidity 
and mortality rates and lower clinical success.
The present study is limited by its retrospective nature, 
with a relatively small and heterogeneous sample size with 
potential selection bias due to the number of patients lost 
to follow-up and the absence of a control group. Previous 
studies have demonstrated that deep sedation adds vari-
ability to pressure values and recommend PPG measure-
ments after the patient had fully recovered from sedation 
[40, 41]. Such changes can be attributed either to direct 
hemodynamic effects of sedative drugs used or to diffi-
culty in accurate measurements of pressure values due to 
changes in the respiratory pattern. In our study, all pa-
tients received general anesthesia with liver hemodynam-
ic values measured exactly under the same conditions be-
fore and after the procedure. Changes in PPG reflect the 
impact of TIPS placement, even though these changes 
from baseline may be affected by general anesthesia, which 
could have under- or overestimated the magnitude of the 
treatment effect. Regarding statistical analysis, we did not 
use logistic regression models as the results of data analy-
sis would be limited by our small sample size, potentially 
leading to inadequate conclusions. Another limitation is 
that follow-up was not standardized; being a referral cen-
ter, many patients that received TIPS returned to their 
original institution after the procedure, making proper 
long-term surveillance difficult. Despite these limitations, 
the present study could provide valuable information as it 
represents real-life experience, and we believe that these 
findings may serve as a basis for further investigations and 
improvements in clinical practice. 
In conclusion, the TIPS procedure is a valid and safe 
option for managing patients with portal hypertension-
related complications refractory to standard treatments, 
mainly ascites and variceal bleeding. However, being a 
procedure with potential complications, careful patient 
selection is essential to improve long-term outcomes.
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